Stock Market Reviews

Read and share opinions on VOR (Vor Biopharma Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Nov 13, 2025
• Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
  Nov 11, 2025
• Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
  Nov 10, 2025
• Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
  Nov 8, 2025
• Vor Bio to Participate in Upcoming Investor Conferences
  Nov 7, 2025
• Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
  Nov 3, 2025
• Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Oct 31, 2025
• Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
  Oct 29, 2025
• Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
  Oct 22, 2025
• Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint
  Oct 17, 2025
• Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
  Oct 17, 2025
• Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
  Oct 16, 2025
• Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
  Oct 14, 2025
• Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
  Sep 29, 2025
• Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
  Sep 23, 2025
• Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
  Sep 17, 2025
• Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
  Sep 12, 2025
• We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
  Sep 7, 2025
• Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
  Sep 2, 2025
• Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
  Aug 27, 2025